Spravato Indications/Uses

SPRAVATO, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), is indicated for adults with treatment-resistant Major Depressive Disorder (MDD), who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode (see Pharmacology: Pharmacodynamics under Actions).
SPRAVATO is indicated, in conjunction with an oral antidepressant, for the treatment of depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
Limitations of Use: The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated (see Pharmacology: Pharmacodynamics under Actions). Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO.
SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established.